BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IBI305 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of IBI305\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07560488-7610@assetmemo.bio
DTSTAMP:20261121T004528Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:IBI305: Phase 2 readout est. (NCT07560488)
DESCRIPTION:IBI305\, phase 2.\nStudy: Ipilimumab N01 Combined With Sintilim
 ab\, Bevacizumab Biosimilar\, and Hepatic Arterial Infusion Chemotherapy a
 s Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular
  Carcinoma\nEstimated primary completion: April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ibi305#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07560488
URL:https://assetmemo.bio/drug/ibi305#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
